Comparison of IA-2 Bridge ELISA and Radiobinding Assays for Progression Risk Assessment in Early-Stage Type 1 Diabetes
Bonifacio, E.; Scholz, M.; Weiss, A.; Ziegler, A.-G.
Show abstract
Stratifying progression from early-stage type 1 diabetes to clinical disease is essential for optimally timing disease-modifying therapies. We previously developed a progression likelihood score (PLS) that includes quantitative IA-2 autoantibody (IA-2A) measurements. This study aligned IA-2A thresholds used for PLS calculation between the radiobinding assay (RBA) and a commercially available RSR IA-2A ELISA to support broader clinical application. Serum samples from 349 children with stage 1 type 1 diabetes were analyzed using both assays. IA-2A positivity was similar by RBA (61.6%) and ELISA (59.0%). Centile-based alignment of ELISA-positive samples defined thresholds corresponding to RBA IA-2A categories. ELISA-derived PLS low (PLS < 0.5), moderate (PLS 0.5-4.0) and high (PLS > 4.0) risk groups stratified progression to stage 3 disease comparably to RBA-derived groups. The 3-year progression rate for children with an ELISA IA-2A PLS >4.0 was 52.4% (95% CI, 30.5- 66.1), similar to the RBA-derived PLS >4.0 group (58.7%; 95% CI, 37.1-72.8). These results demonstrate that the commercial ELISA can be used for PLS-based risk stratification.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.